Vivoryon Therapeutics NV
AEX:VVY
Cash Flow Statement
Cash Flow Statement
Vivoryon Therapeutics NV
| Dec-2014 | Jun-2015 | Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Sep-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||||
| Net Income |
(11)
|
(14)
|
(14)
|
(13)
|
(14)
|
(12)
|
(8)
|
(8)
|
(8)
|
(7)
|
(8)
|
(12)
|
(17)
|
(21)
|
(16)
|
(12)
|
(13)
|
(28)
|
(26)
|
(28)
|
(31)
|
(21)
|
(12)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Deffered Taxes |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
3
|
3
|
3
|
4
|
5
|
2
|
2
|
|
| Other Non-Cash Items |
1
|
2
|
1
|
1
|
1
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
1
|
1
|
6
|
8
|
7
|
5
|
2
|
2
|
|
| Cash Taxes Paid |
(0)
|
0
|
(0)
|
0
|
(0)
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Change in Working Capital |
(0)
|
(1)
|
0
|
(1)
|
(0)
|
(1)
|
(4)
|
(1)
|
1
|
0
|
(4)
|
(3)
|
2
|
5
|
(2)
|
(1)
|
(4)
|
0
|
(13)
|
0
|
11
|
(1)
|
(0)
|
|
| Cash from Operating Activities |
(11)
N/A
|
(13)
-25%
|
(12)
+8%
|
(13)
-7%
|
(13)
-2%
|
(14)
-4%
|
(12)
+12%
|
(9)
+28%
|
(7)
+20%
|
(6)
+9%
|
(12)
-83%
|
(15)
-25%
|
(14)
+4%
|
(14)
-1%
|
(15)
-6%
|
(11)
+25%
|
(15)
-33%
|
(22)
-46%
|
(32)
-46%
|
(22)
+32%
|
(15)
+32%
|
(19)
-30%
|
(10)
+45%
|
|
| Investing Cash Flow | ||||||||||||||||||||||||
| Capital Expenditures |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
0
|
(0)
|
(0)
|
|
| Other Items |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
(0)
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
(10)
|
0
|
10
|
0
|
|
| Cash from Investing Activities |
1
N/A
|
1
-3%
|
(0)
N/A
|
(0)
-1 100%
|
(0)
-3%
|
0
N/A
|
0
N/A
|
1
+103%
|
0
-51%
|
(0)
N/A
|
(0)
-236%
|
(1)
-1 213%
|
(1)
-4%
|
(0)
+86%
|
(0)
-4%
|
(0)
+70%
|
(0)
+79%
|
(0)
-117%
|
(0)
-54%
|
(11)
-52 470%
|
(1)
+91%
|
10
N/A
|
(0)
N/A
|
|
| Financing Cash Flow | ||||||||||||||||||||||||
| Net Issuance of Common Stock |
23
|
0
|
14
|
0
|
15
|
0
|
0
|
0
|
0
|
8
|
51
|
0
|
0
|
0
|
1
|
1
|
22
|
36
|
41
|
26
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other |
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(1)
|
(2)
|
0
|
0
|
0
|
0
|
(2)
|
(3)
|
(3)
|
(3)
|
(2)
|
(0)
|
0
|
0
|
|
| Cash from Financing Activities |
26
N/A
|
21
-17%
|
13
-41%
|
13
+0%
|
14
+10%
|
14
+0%
|
0
-99%
|
0
+2%
|
0
N/A
|
8
N/A
|
49
+546%
|
42
-16%
|
(0)
N/A
|
(0)
N/A
|
1
N/A
|
(1)
N/A
|
19
N/A
|
33
+78%
|
37
+11%
|
24
-35%
|
1
-98%
|
(0)
N/A
|
(0)
-2%
|
|
| Change in Cash | ||||||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Net Change in Cash |
16
N/A
|
10
-42%
|
0
-95%
|
(1)
N/A
|
1
N/A
|
0
-72%
|
(12)
N/A
|
(8)
+34%
|
(7)
+15%
|
1
N/A
|
38
+2 785%
|
26
-30%
|
(15)
N/A
|
(15)
+4%
|
(15)
+0%
|
(12)
+20%
|
5
N/A
|
12
+161%
|
5
-56%
|
(8)
N/A
|
(15)
-89%
|
(9)
+39%
|
(11)
-15%
|
|
| Free Cash Flow | ||||||||||||||||||||||||
| Free Cash Flow |
(11)
N/A
|
(13)
-25%
|
(12)
+8%
|
(13)
-8%
|
(13)
-2%
|
(14)
-3%
|
(12)
+12%
|
(9)
+28%
|
(7)
+20%
|
(6)
+9%
|
(12)
-83%
|
(15)
-30%
|
(14)
+7%
|
(14)
+3%
|
(15)
-6%
|
(11)
+22%
|
(15)
-33%
|
(22)
-46%
|
(32)
-46%
|
(22)
+31%
|
(15)
+33%
|
(19)
-30%
|
(11)
+45%
|
|